Competitiveness of New Drug Clinical Development in Taiwan and Other Asian Pacific Countries

碩士 === 國立臺灣大學 === 國際企業學研究所 === 97 === Innovative new drug development is always a key success factor for biotech and pharmaceutical companies in order for business continuity. The dynamics of drug development is one of the defining characteristics of the biotech and pharmaceutical industry. Owing t...

Full description

Bibliographic Details
Main Authors: Shu-Hui Fan, 樊淑惠
Other Authors: Heng-Chiang Huang
Format: Others
Language:zh-TW
Published: 2009
Online Access:http://ndltd.ncl.edu.tw/handle/90330472990369367481
Description
Summary:碩士 === 國立臺灣大學 === 國際企業學研究所 === 97 === Innovative new drug development is always a key success factor for biotech and pharmaceutical companies in order for business continuity. The dynamics of drug development is one of the defining characteristics of the biotech and pharmaceutical industry. Owing to the high failure rate and dramatically growing cost, the biotech and pharmaceutical industry is facing tremendous new challenges in innovative drug research and development. Asian Pacific pharmaceutical sales revenue has continued to boom in recent years. Meanwhile, most Asian Pacific countries strive to get more and more involved in global clinical development. How to strengthen international competitiveness has become a key issue for attracting global investment in innovative new drug development. The thesis focuses on the establishment of research and development bases for the acceleration of innovation in new drug research and strengthening of international competitiveness of the Asian Pacific biotech and pharmaceutical industry. By analyzing the competiveness among Asian Pacific countries, we expect to come up with valid suggestions and strategies for the stakeholders including government, academia and industry to strengthen international competitiveness in order to promote biotech and pharmaceutical research and development.